The Relevance of Clonal Hematopoiesis to Degenerative Aging Remains Uncertain

Key Takeaways

• CH arises from accumulated stem‑cell mutations with age
• Linked to cancer, cardiovascular disease, and inflammatory aging
• Definitions and detection vary, causing inconsistent study results
• May both reflect and exacerbate inflammageing and immunosenescence
• Interacts with epigenetic age acceleration and telomere shortening

Summary

Clonal hematopoiesis (CH) is the age‑related expansion of blood‑cell clones carrying somatic mutations acquired in hematopoietic stem cells. Detectable CH appears in roughly 10 % of individuals over 70, making it a common form of somatic mosaicism. While CH is a well‑established risk factor for hematologic cancers, emerging data link it to cardiovascular disease, inflammageing, immunosenescence, epigenetic age acceleration, and telomere shortening. However, inconsistent definitions and detection methods leave its direct contribution to degenerative aging uncertain.

Pulse Analysis

Clonal hematopoiesis (CH) describes the expansion of blood‑cell lineages that carry somatic mutations acquired in hematopoietic stem cells. As individuals age, random DNA damage outpaces repair, allowing mutant clones to dominate a fraction of the peripheral blood. Modern sequencing can detect point mutations, small indels, and loss‑of‑chromosome events at variant allele frequencies as low as 1 %. Population studies now estimate that up to 10 % of people over 70 exhibit detectable CH, making it one of the most common age‑related genomic alterations.

Beyond its role as a cancer precursor, CH has been associated with cardiovascular disease, chronic inflammation, and accelerated epigenetic aging. Mutant clones often carry driver genes such as DNMT3A, TET2, or ASXL1, which can skew cytokine production and promote a pro‑inflammatory milieu known as inflammageing. This heightened inflammation feeds back to expand the mutant population, creating a vicious cycle that also impairs adaptive immunity, a hallmark of immunosenescence. Correlative studies further link CH to shorter telomeres and higher epigenetic age scores, suggesting it may both reflect and amplify systemic aging processes.

Despite mounting associations, causality remains unresolved because CH definitions, sequencing depth, and cohort characteristics differ across studies. Some investigations report independent risk contributions from distinct CH subtypes, while others attribute observed effects to shared risk factors such as smoking or clonal expansion driven by inflammation. Clarifying whether CH is a modifiable driver of age‑related disease could open therapeutic avenues, including targeted gene editing or anti‑inflammatory interventions. Ongoing longitudinal biobanks and single‑cell analyses promise to disentangle these relationships, positioning CH as a potential biomarker and intervention point for healthy longevity.